MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

Начало・Списък с акции・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

479.12 -3.73

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

465.74

Максимум

495.37

Ключови измерители
By Trading Economics
Приходи	-72M -114M
Продажби	74M 287M
Марж на печалбата	-39.75
Служители	528
EBITDA	-68M -106M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+32.61% upside

Дивиденти
By Dow Jones
Следващи печалби	25.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	2.2B 11B
Предишно отваряне	482.85
Предишно затваряне	479.12

Настроения в новините

By Acuity

26%

74%

63 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

263.2 / 277.1 Подкрепа & съпротива

Madrigal Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.01.2026 г., 18:41 ч. UTC

Печалби

SLB Readies Rapid Expansion in Venezuela -- 2nd Update

23.01.2026 г., 22:30 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

23.01.2026 г., 22:30 ч. UTC

Пазарно говорене

Trump Seen Using Canada's EV Deal With China to Extract Concessions -- Market Talk

23.01.2026 г., 22:03 ч. UTC

Печалби

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

23.01.2026 г., 21:52 ч. UTC

Печалби

Придобивния, сливания и поглъщания

GE Aerospace's Earnings Worried the Market. What CEO Larry Culp Says. -- Barrons.com

23.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

23.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

23.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

23.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

23.01.2026 г., 21:39 ч. UTC

Печалби

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 5th Update

23.01.2026 г., 21:15 ч. UTC

Придобивния, сливания и поглъщания

Eaton Completes Acquisition Of Ultra PCS Limited, Expanding Capabilities And Solutions For Next-generation Aerospace And Defense Markets >ETN

23.01.2026 г., 21:12 ч. UTC

Печалби

CSX Stock Rises After Earnings Miss Estimates. It's the Outlook. -- Barrons.com

23.01.2026 г., 20:31 ч. UTC

Печалби

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

23.01.2026 г., 20:12 ч. UTC

Пазарно говорене

Oil Futures Rebound on Iran, Russia-Ukraine Risk -- Market Talk

23.01.2026 г., 20:07 ч. UTC

Пазарно говорене

U.S. Natural Gas Posts Record Weekly Gain on Winter Storm -- Market Talk

23.01.2026 г., 19:36 ч. UTC

Пазарно говорене

Dollar Weakens Against Yen Amid Intervention Chatter -- Market Talk

23.01.2026 г., 19:30 ч. UTC

Пазарно говорене

Печалби

Intel's Stock Has Limited Catalysts Ahead, Analysts Say -- Market Talk

23.01.2026 г., 19:18 ч. UTC

Пазарно говорене

Gold and Silver Step Up to More Records -- Market Talk

23.01.2026 г., 19:15 ч. UTC

Печалби

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 4th Update

23.01.2026 г., 18:53 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 1 to 411 -- Market Talk

23.01.2026 г., 18:21 ч. UTC

Печалби

Week's Best: Schwab's Assets and Profits Keep Climbing -- Barrons.com

23.01.2026 г., 18:19 ч. UTC

Пазарно говорене

Intel Seen as Increasingly Confident on Demand -- Market Talk

23.01.2026 г., 17:59 ч. UTC

Печалби

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 3rd Update

23.01.2026 г., 17:57 ч. UTC

Пазарно говорене

Intel Could Sign Deals With Big Tech Players for 14A -- Market Talk

23.01.2026 г., 17:57 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

23.01.2026 г., 17:34 ч. UTC

Пазарно говорене

Печалби

Intel's Supply Challenges Seen Benefiting AMD -- Market Talk

23.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

23.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

23.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

23.01.2026 г., 17:13 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Madrigal Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

32.61% нагоре

12-месечна прогноза

Среден 660.44 USD 32.61%

Висок 900 USD

Нисък 533 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Madrigal Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Madrigal Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

263.2 / 277.1Подкрепа & съпротива

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

63 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.